



Curriculum Vitae

Peter Steen Hansen

Speciallæge i kardiologi, Ph.D., dr. med., FEHRA (2016)

Lunddalsvej 5

6800 Varde

Denmark

Tlf.: +45 2023 2692

e-mail: psh@molholm.dk

Aktuel stilling: *Klinikchef, HjerteCenter Mølholm, Vejle, Denmark*

Tidligere beskæftigelser inkluderer:

2007-2017 *HjerteCenter Varde, Danmark. Specialeansvarlig, kardiologi.*

1999-2007 *Hjertemedicinsk afd. Aarhus Universitetshospital Skejby. Overlæge.*

1998-1999 *AK St. Georg, Hamburg (post-doc fellow)*

1985-1998 *Postgraduat uddannelse i kirurgi, intern medicin og kardiologi.*

1990-1993 *Ph.D. fellow*

Speciallæge Intern Medicin/kardiologi: 1999

Klinisk EP-erfaring:

Mere end 8.000 kateterablationer, inklusive atrieflimren, incisional flagren, VT, GUCH.

Videnskabelig erfaring:

Mange studier indenfor ablation af VT, arytmier efter hjertekirurgi og atrieflimren, samt indenfor forskellige aspekter indenfor behandling med pacemaker, ICD og CRT-devices.

Mere end 85 peer-reviewed internationale publikationer (se separat liste)

Afhandlinger:

*"DNA polymorphism at the apolipoprotein B locus and association with plasma lipid concentrations and ischemic heart disease". **Ph.D.-afhandling**; Aarhus Universitet, Danmark 1994*

"Familial Defective Apolipoprotein B-100". Dan Med Bull 1998;45:370-382.
Doktorafhandling; Aarhus Universitet, Danmark 1998

Lærebog: Klinisk Elektrokardiologi (518p). Bjarne Sigurd, Steen Pehrson, Peter Steen Hansen.
FADL's Forlag 2014.

Ansvarlig for uddannelsesmæssige aktiviteter såvel præ- som postgraduate, inclusive ansvar gennem 7 år for træning i brug af 3D elektroanatomisk mappingsystem (Carto) ved European Surgical Institute (ESI), Norderstedt, Tyskland.

Medlemsskab af selskaber::

Fellow of the European Heart Rhythm Association (FEHRA)

Dansk Cardiologisk Selskab, European Society of Cardiology, European Heart Rhythm Association

Nationale Danske Register for Ablationer (www.ablation.dk), Bestyrelsesmedlem

2001-2008 formand/næst-formand i arbejdsgruppen for elektrofysiologi og pacemaker/ICD, Dansk Cardiologisk Selskab

2004-2007 "Hjertefølgegruppen", Sundhedsstyrelsen.

Kongresdeltagelse:

Deltager årligt i Dansk Cardiologisk Selskabs årsmøde.
Alternierende deltagelse i det årlige amerikanske "Atrial fibrillation Symposium" og den europæiske "European Heart Rhythm Society Congress".

Sprog: Taler engelsk, tysk, dansk og skandinavisk.. Læser medicinsk fransk, spansk og italiensk.

Publikationer:

Electrophysiology, pacing and cardiac resynchronization therapy:

1. Peri-procedural complications and one-year outcomes after catheter ablation for treatment of atrial fibrillation in elderly patients: A nationwide Danish cohort study.
Jesper Nielsen, Kristian Hay Kragholm, Sofie Brix Christensen, Arne Johannesen, Christian Torp-Pedersen, Steen Buus Kristiansen, Peter Karl Jacobsen, Peter Steen Hansen, Mogens Stig Djurhus, Christoffer Polcwiartek, Peter Søgaard, Anna Margrethe Thøgersen, Uffe Jakob Ortved Gang, Ole Dan Jørgensen, Filip Ericsson, Sam Riahi. *Journal of Geriatric Cardiology* 2021, *in press*.
2. Discontinuation of oral anticoagulation and risk of stroke and death after ablation for typical atrial flutter: A nation-wide Danish cohort study.
Giehm-Reese M, Johansen MN, Kronborg MB, Jensen HK, Gerdes C, Kristensen J, Johannessen A, Jacobsen PK, Djurhuus MS, Hansen PS, Riahi S, Nielsen JC.
Int J Cardiol 2021;Feb 27 online.

3. Recurrent atrial flutter ablation and incidence of atrial fibrillation ablation after first-time ablation for typical atrial flutter: A nation-wide Danish cohort study.
Giehm-Reese M, Kronborg MB, Lukac P, Kristiansen SB, Nielsen JM, Johannessen A, Jacobsen PK, Djurhuus MS, Riahi S, Hansen PS, Nielsen JC.
Int J Cardiol 2020;Jan 1:298:44-51
4. Gender and age differences in symptoms and health-related quality of life in patients with atrial fibrillation referred for catheter ablation.
Walfridsson U, Steen Hansen P, Charitakis E, Almroth H, Jönsson A, Karlsson LO, Liuba I, Samo Ayoub R, Poci D, Holmqvist F, Kongstad O, Walfridsson H.
Pacing Clin Electrophysiol 2019;42:1431-1439
5. The impact of supraventricular ectopic complexes in different age groups and risk of recurrent atrial fibrillation after antiarrhythmic medication or catheter ablation.
Alhede C, Lauridsen TK, Johannessen A, Dixen U, Jensen JS, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, Pehrson S, Englund A, Hartikainen J, Hansen PS, Nielsen JC, Jons C.
Int J Cardiol. 2018 Jan 1;250:122-127
6. Antiarrhythmic medication is superior to catheter ablation in suppressing supraventricular ectopic complexes in patients with atrial fibrillation.
Alhede C, Lauridsen TK, Johannessen A, Dixen U, Jensen JS, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, Pehrson S, Englund A, Hartikainen J, Hansen PS, Nielsen JC, Jons C.
Int J Cardiol. 2017 Oct 1;244:186-191
7. Higher burden of supraventricular ectopic complexes early after catheter ablation for atrial fibrillation is associated with increased risk of recurrent atrial fibrillation.
Alhede C, Johannessen A, Dixen U, Jensen JS, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, Pehrson S, Englund A, Hartikainen J, Hansen PS, Nielsen JC, Jons C.
Europace. 2018 Jan 1;20(1):50-57
8. Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation.
Hansen PS, Sanchez R, Walfridsson H.
Dan Med J. 2016 Feb;63(2).
9. Impact of Substrate Modification by Catheter Ablation on ICD Interventions in Patients with Unstable Ventricular Arrhythmias and Coronary Artery Disease: Results from the Multicenter Randomized Controlled Substrate Modification Study (SMS).
Karl-Heinz Kuck, Roland Tilz, Thomas Deneke, Boris A. Hoffmann, Rodolfo Ventura, **Peter Steen Hansen**, Markus Zarse, Stefan H. Hohnloser, Josef Kautzner, Stephan Willems.
Circulation Arrhythmia and Electrophysiology 2017;10:e004422. DOI: 10.1161/CIRCEP.116.004422
10. Nielsen JC, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Pehrson SM, Englund A, Hartikainen J, Mortensen LS, **Hansen PS**; for the MANTRA-PAF Investigators. Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation. Five-year outcome in a randomized clinical trial. Heart 2016 (accepted).
11. Raatikainen MJ, Hakalahti A, Uusimaa P, Nielsen JC, Johannessen A, Hindricks G, Walfridsson H, Pehrson S, Englund A, Hartikainen J, Kongstad O, Mortensen LS, **Hansen PS**; MANTRA-PAF investigators. Radiofrequency catheter ablation maintains its efficacy better than antiarrhythmic medication in patients with paroxysmal atrial fibrillation: On-treatment analysis of the randomized controlled MANTRA-PAF trial. Int J Cardiol 2015;198:108-14
12. Walfridsson H, Walfridsson U, Nielsen JC, Johannessen A, Raatikainen P, Janzon M, Levin LA, Aronsson M, Hindricks G, Kongstad O, Pehrson S, Englund A, Hartikainen J, Mortensen LS, **Hansen PS**. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial. Europace 2015;17:215-21
13. Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, Pehrson S, Englund A, Hartikainen J, Mortensen LS, **Hansen PS**. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012 Oct 25;367(17):1587-95.
14. Arbelo E, Brugada J, Hindricks G, Maggioni A, Tavazzi L, Vardas P, Anselme F, Inama G, Jais P, Kalarus Z, Kautzner J, Lewalter T, Mairesse G, Perez-Villacastin J, Riahi S, Taborisky M, Theodorakis G, Trines S; Atrial Fibrillation Ablation Pilot Study Investigators. ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. Europace. 2012 Aug;14(8):1094-103.

15. Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E, Pitschner HF, Kautzner J, Schumacher B, **Hansen PS**; VTACH study group. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. *Lancet* 2010 Jan 2;375(9708):31-40.
16. Jons C, **Hansen PS**, Johannessen A, Hindricks G, Raatikainen P, Kongstad O, Walfridsson H, Pehrson S, Almroth H, Hartikainen J, Petersen AK, Mortensen LS, Nielsen JC; MANTRA-PAF Investigators. The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) trial: clinical rationale, study design, and implementation. *Europace*. 2009 Jul;11(7):917-23.
17. de Groot NM, Lukac P, Blom NA, van Kuijk JP, Pedersen AK, **Hansen PS**, Delacretaz E, Schalij MJ. Long-term outcome of ablative therapy of postoperative supraventricular tachycardias in patients with univentricular heart: a European multicenter study. *Circ Arrhythm Electrophysiol*. 2009 Jun;2(3):242-8.
18. Pontoppidan J, Nielsen JC, Poulsen SH, **Hansen PS**. Symptomatic and asymptomatic atrial fibrillation after pulmonary vein ablation and the impact on quality of life. *Pacing Clin Electrophysiol*. 2009 Jun;32(6):717-26.
19. Pontoppidan J, Nielsen JC, Poulsen SH, Jensen HK, Walfridsson H, Pedersen AK, **Hansen PS**. Prophylactic cavotricuspid isthmus block during atrial fibrillation ablation in patients without atrial flutter: a randomised controlled trial. *Heart* 2009 Jun;95(12):994-9.
20. Staehr PB, **Hansen PS**, Eiskjaer H, Dalhøj J, Videbaek L. [Frequent ventricular ectopy as reversible cause of dilated cardiomyopathy]. *Ugeskr Laeger*. 2008 Oct 20;170(43):3436. Danish.
21. Albertsen AE, Nielsen JC, Poulsen SH, Mortensen PT, Pedersen AK, **Hansen PS**, Jensen HK, Egeblad H. Biventricular pacing preserves left ventricular performance in patients with high-grade atrio-ventricular block: a randomized comparison with DDD(R) pacing in 50 consecutive patients. *Europace*. 2008 Mar;10(3):314-20.
22. Albertsen AE, Nielsen JC, Poulsen SH, Mortensen PT, Pedersen AK, **Hansen PS**, Jensen HK, Egeblad H. DDD(R)-pacing, but not AAI(R)-pacing induces left ventricular desynchronization in patients with sick sinus syndrome: tissue-Doppler and 3D echocardiographic evaluation in a randomized controlled comparison. *Europace*. 2008 Feb;10(2):127-33.
23. Lukac P, Hjortdal VE, Pedersen AK, Mortensen PT, Jensen HK, **Hansen PS**. Prevention of atrial flutter with cryoablation may be proarrhythmogenic. *Ann Thorac Surg*. 2007 May;83(5):1717-23.
24. Lukac P, Hjortdal VE, Pedersen AK, Mortensen PT, Jensen HK, **Hansen PS**. Superior transseptal approach to mitral valve is associated with a higher need for pacemaker implantation than the left atrial approach. *Ann Thorac Surg*. 2007 Jan;83(1):77-82.
25. Lukac P, Hjortdal V, Pedersen AK, Jensen HK, Mortensen PT, **Hansen PS**. The superior transseptal surgical approach to mitral valve creates slow conduction. *Pacing Clin Electrophysiol*. 2006 Jul;29(7):719-26.
26. Lukac P, Hjortdal VE, Pedersen AK, Mortensen PT, Jensen HK, **Hansen PS**. Atrial incision affects the incidence of atrial tachycardia after mitral valve surgery. *Ann Thorac Surg*. 2006 Feb;81(2):509-13.
27. Pontoppidan J, Nielsen JC, Poulsen SH, Mortensen PT, Pedersen AK, Jensen HK, **Hansen PS**. [Radio frequency of atrial fibrillation: results from 102 consecutive patients --secondary publication]. *Ugeskr Laeger*. 2006 Jan 30;168(5):478-80. Danish.
28. Gerdes JC, **Hansen PS**. [Electrocardiography. Tips & tricks]. *Ugeskr Laeger*. 2006 Jan 16;168(3):274-6. Danish.
29. Pontoppidan J, Nielsen JC, Poulsen SH, Mortensen PT, Pedersen AK, Jensen HK, **Hansen PS**. Radiofrequency ablation of atrial fibrillation: effectiveness and safety in 102 consecutive patients. *Heart*. 2005 Dec;91(12):1611-2.
30. Smerup M, Hjertholm T, Johnsen SP, Pedersen AK, **Hansen PS**, Mortensen PT, Hansen OK, Hjortdal V. Pacemaker implantation after congenital heart surgery: risk and prognosis in a population-based follow-up study. *Eur J Cardiothorac Surg*. 2005 Jul;28(1):61-8.
31. Albertsen AE, Nielsen JC, Pedersen AK, **Hansen PS**, Jensen HK, Mortensen PT. Left ventricular lead performance in cardiac resynchronization therapy: impact of lead localization and complications. *Pacing Clin Electrophysiol*. 2005 Jun;28(6):483-8.
32. Lukac P, Pedersen AK, Mortensen PT, Jensen HK, Hjortdal V, **Hansen PS**. Ablation of atrial tachycardia after surgery for congenital and acquired heart disease using an electroanatomic mapping system: Which circuits to expect in which substrate? *Heart Rhythm*. 2005 Jan;2(1):64-72.
33. Tanner H, Lukac P, Schwick N, Fuhrer J, Pedersen AK, **Hansen PS**, Delacretaz E. Irrigated-tip catheter ablation of intraatrial reentrant tachycardia in patients late after surgery of congenital heart disease. *Heart Rhythm*. 2004 Sep;1(3):268-75.

34. Svendsen JH, Haarbo J, **Hansen PS**, Møller M, Pehrson SM.[Invasive treatment of cardiac arrhythmias. A survey of activities and expectations concerning the development in the coming decades]. *Ugeskr Laeger*. 2004 May 10;166(20):1879-81. Danish.
35. **Hansen PS**, Pehrson S.[Treatment of atrial fibrillation--paradigmatic shift or confirmation of earlier practice? The Danish Society of Cardiology]. *Ugeskr Laeger*. 2004 Mar 15;166(12):1104. Danish.
36. **Hansen PS**. [Treatment of atrial fibrillation--status in the year 2003]. *Ugeskr Laeger*. 2004 Mar 1;166(10):887. Danish.
37. Sogaard P, Egeblad H, Pedersen AK, Kim WY, Kristensen BO, **Hansen PS**, Mortensen PT. Sequential versus simultaneous biventricular resynchronization for severe heart failure: evaluation by tissue Doppler imaging. *Circulation*. 2002 Oct 15;106(16):2078-84.
38. Pehrson SM, **Hansen PS**. [Treatment of heart arrhythmias. The Danish Cardiology Society]. *Ugeskr Laeger*. 2002 Mar 18;164(12):1648. Danish.
39. Hebe J, **Hansen P**, Ouyang F, Volkmer M, Kuck KH. Radiofrequency catheter ablation of tachycardia in patients with congenital heart disease. *Pediatr Cardiol*. 2000 Nov-Dec;21(6):557-75.
40. Hebe J, Krings G, **Hansen P**, Volkmer M, Ouyang F, Kuck KH. [Arrhythmias in patients with congenital heart disease and their impact on prognosis]. *Herz*. 1999 Jun;24(4):315-34. Review. German.

Genetic epidemiology, molecular genetic, general cardiology, cardiac surgery:

41. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, **Hansen PS**, Kesäniemi YA, Faergeman O. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. *Circulation*. 2000 Mar 28;101(12):1366-71.
42. Mogensen J, Egeblad H, **Hansen PS**, Jensen HK, Thuesen L. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. A new therapeutic option]. *Ugeskr Laeger*. 2000 Mar 6;162(10):1371-5. Danish.
43. Raungaard B, Heath F, **Hansen PS**, Brorholt-Petersen JU, Jensen HK, Faergeman O. Flow cytometric assessment of LDL ligand function for detection of heterozygous familial defective apolipoprotein B-100. *Clin Chem*. 2000 Feb;46(2):224-33.
44. Pedersen AK, **Hansen PS**, Benn M. A reply. *Eur Heart J*. 2000 Jan 1;21(1):79-80. No abstract available.
45. Jensen HK, Jensen LG, Holst HU, Andreassen PH, **Hansen PS**, Larsen ML, Kølvrå S, Bolund L, Gregersen N, Faergeman O. Normolipidemia and hypercholesterolemia in persons heterozygous for the same 1592 + 5G --> A splice site mutation in the low-density lipoprotein receptor gene. *Clin Genet*. 1999 Nov;56(5):378-88.
46. Jensen HK, Jensen LG, Meinertz H, **Hansen PS**, Gregersen N, Faergeman O. Spectrum of LDL receptor gene mutations in Denmark: implications for molecular diagnostic strategy in heterozygous familial hypercholesterolemia. *Atherosclerosis*. 1999 Oct;146(2):337-44.
47. Mogensen J, Klausen IC, Pedersen AK, Egeblad H, Bross P, Kruse TA, Gregersen N, **Hansen PS**, Baandrup U, Borglum AD. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. *J Clin Invest*. 1999 May 15;103(10):R39-43.
48. Benn M, **Hansen PS**, Pedersen AK. QT dispersion in patients with arrhythmogenic right ventricular dysplasia. *Eur Heart J*. 1999 May;20(10):764-70.
49. **Hansen PS**. Familial defective apolipoprotein B-100. *Dan Med Bull*. 1998 Sep;45(4):370-82. Review.
50. Kotze MJ, Peeters AV, Loubser O, Theart L, du Plessis L, Hayes VM, de Jong G, de Villiers JN, Lombard CJ, **Hansen PS**, Raal FJ. Familial hypercholesterolemia: potential diagnostic value of mutation screening in a pediatric population of South Africa. *Clin Genet*. 1998 Jul;54(1):74-8.
51. Lund B, **Hansen PS**, Benn M, Pedersen AK. [Hereditary long QT syndrome]. *Ugeskr Laeger*. 1998 Jun 8;160(24):3533-9. Review. Danish.
52. Benn M, **Hansen PS**, Lund B, Schiønning JD, Baandrup U, Pedersen AK. [Arrhythmogenic right ventricular cardiomyopathy]. *Ugeskr Laeger*. 1998 Mar 2;160(10):1454-9. Review. Danish.
53. Klausen IC, Sjøel A, **Hansen PS**, Gerdes LU, Møller L, Lemming L, Schroll M, Faergeman O. Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. *Atherosclerosis*. 1997 Jul 11;132(1):77-84.

54. Jensen HK, Holst H, Jensen LG, Jørgensen MM, Andreasen PH, Jensen TG, Andresen BS, Heath F, **Hansen PS**, Neve S, Kristiansen K, Faergeman O, Kølvrå S, Bolund L, Gregersen N. A common W556S mutation in the LDL receptor gene of Danish patients with familial hypercholesterolemia encodes a transport-defective protein. *Atherosclerosis*. 1997 May;131(1):67-72.
55. **Hansen PS**, Defesche JC, Kastelein JJ, Gerdes LU, Frazza L, Gerdes C, Tato F, Jensen HK, Jensen LG, Klausen IC, Faergeman O, Schuster H. Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countries. *Arterioscler Thromb Vasc Biol*. 1997 Apr;17(4):741-7.
56. Jensen HK, Jensen TG, Faergeman O, Jensen LG, Andresen BS, Corydon MJ, Andreasen PH, **Hansen PS**, Heath F, Bolund L, Gregersen N. Two mutations in the same low-density lipoprotein receptor allele act in synergy to reduce receptor function in heterozygous familial hypercholesterolemia. *Hum Mutat*. 1997;9(5):437-44.
57. Jensen HK, Jensen LG, Heath F, Melsen F, **Hansen PS**, Meinertz H, Bolund L, Gregersen N, Faergeman O. Phenotypic characterization of a patient homozygous for the D558N LDL receptor gene mutation. *Clin Genet*. 1996 Nov;50(5):388-92.
58. Klausen IC, Gerdes LU, **Hansen PS**, Lemming L, Gerdes C, Faergeman O. Effects of apoE gene polymorphism on Lp(a) concentrations depend on the size of apo(a): a study of 466 white men. *J Mol Med (Berl)*. 1996 Nov;74(11):685-90.
59. Gerdes LU, Gerdes C, **Hansen PS**, Klausen IC, Faergeman O, Dyerberg J. The apolipoprotein E polymorphism in Greenland Inuit in its global perspective. *Hum Genet*. 1996 Nov;98(5):546-50.
60. Gerdes LU, Gerdes C, **Hansen PS**, Klausen IC, Faergeman O. Are men carrying the apolipoprotein epsilon 4- or epsilon 2 allele less fertile than epsilon 3 epsilon 3 genotypes? *Hum Genet*. 1996 Aug;98(2):239-42.
61. Jensen HK, Jensen LG, **Hansen PS**, Faergeman O, Gregersen N. High sensitivity of the single-strand conformation polymorphism method for detecting sequence variations in the low-density lipoprotein receptor gene validated by DNA sequencing. *Clin Chem*. 1996 Aug;42(8 Pt 1):1140-6.
62. Heath F, Jensen TG, **Hansen PS**, Jensen LG, Vissinger H, Moestrup SK, Pedersen S, Kølvrå S, Bolund L, Faergeman O. A flow cytometric competition technique for measuring interaction of LDL with cellular LDL-receptors applied to patients with mutant (Arg3500-->Gln) apolipoprotein B. *Z Gastroenterol*. 1996 Jun;34 Suppl 3:21-4.
63. Jensen HK, Jensen LG, **Hansen PS**, Bolund L, Faergeman O, Gregersen N. A G-1-to-A acceptor splice site LDLR mutant allele leads to reduced relative transcript levels in patients with heterozygous familial hypercholesterolemia. *Clin Genet*. 1996 Apr;49(4):175-9.
64. Pedersen SB, **Hansen PS**, Lund S, Andersen PH, Odgaard A, Richelsen B. Identification of oestrogen receptors and oestrogen receptor mRNA in human adipose tissue. *Eur J Clin Invest*. 1996 Apr;26(4):262-9.
65. Jensen HK, Jensen LG, **Hansen PS**, Faergeman O, Gregersen N. An Iranian-Armenian LDLR frameshift mutation causing familial hypercholesterolemia. *Clin Genet*. 1996 Feb;49(2):88-90.
66. Jensen HK, Jensen LG, **Hansen PS**, Faergeman O, Gregersen N. The Trp23-Stop and Trp66-Gly mutations in the LDL receptor gene: common causes of familial hypercholesterolemia in Denmark. *Atherosclerosis*. 1996 Feb;120(1-2):57-65.
67. Jensen HK, Jensen LG, **Hansen PS**, Faergeman O, Gregersen N. Two point mutations (313 + 1G --> A and 313 + 1G --> T) in the splice donor site of intron 3 of the low-density lipoprotein receptor gene are associated with familial hypercholesterolemia. *Hum Mutat*. 1996;7(3):269-71.
68. Klausen IC, **Hansen PS**, Povlsen JV, Gerdes LU, Lemming L, Faergeman O. A unique pattern of apo(a) polymorphism in an isolated east Greenlandic Inuit (Eskimo) population. *Eur J Epidemiol*. 1995 Oct;11(5):563-8.
69. Gerdes C, Gerdes LU, **Hansen PS**, Faergeman O. Polymorphisms in the lipoprotein lipase gene and their associations with plasma lipid concentrations in 40-year-old Danish men. *Circulation*. 1995 Oct 1;92(7):1765-9.
70. Jensen HK, **Hansen PS**, Jensen LG, Kristensen MJ, Klausen IC, Kjeldsen M, Lemming L, Bolund L, Gregersen N, Faergeman O. Complexity of molecular genetics of dyslipidemia in a family highly susceptible to ischemic heart disease. *Clin Genet*. 1995 Jul;48(1):23-8.
71. **Hansen PS**, Kassem M, Brixen K, Klausen IC, Mosekilde L, Faergeman O. Effect of short-term treatment with recombinant human growth hormone on lipids and lipoproteins in women and men without growth hormone disturbances. *Metabolism* 1995 Jun;44(6):725-9.
72. Nissen H, **Hansen PS**, Faergeman O, Hørder M. Mutation screening of the codon 3500 region of the apolipoprotein B gene by denaturing gradient-gel electrophoresis. *Clin Chem*. 1995 Mar;41(3):419-23.
73. Klausen IC, Hegedüs L, **Hansen PS**, Nielsen FE, Gerdes LU, Faergeman O. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with hyperthyroidism. *J Mol Med (Berl)*. 1995 Jan;73(1):41-6.

74. **Hansen PS**, Meinertz H, Gerdes LU, Klausen IC, Faergeman O. Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study. *Clin Investig*. 1994 Dec;72(12):1065-70.
75. **Hansen PS**, Nørgaard-Petersen B, Meinertz H, Jensen HK, Hansen AB, Klausen IC, Gerdes LU, Faergeman O. Incidence of the apolipoprotein B-3500 mutation in Denmark. *Clin Chim Acta*. 1994 Oct 14;230(1):101-4.
76. Jensen HK, Jensen LG, **Hansen PS**, Petersen LS, Gerdes LU, Bolund L, Faergeman O, Gregersen N. An alanine29-serine variant in exon 2 of the low density lipoprotein receptor gene: no association with hypercholesterolemia. *Clin Genet*. 1994 Aug;46(2):214-5. No abstract available.
77. **Hansen PS**. [Cholesterol reduction: ischemic heart disease and mortality from non-ischemic heart diseases]. *Ugeskr Laeger*. 1994 Apr 25;156(17):2608-9. Danish. No abstract available.
78. **Hansen PS**, Meinertz H, Jensen HK, Fruergaard P, Launbjerg J, Klausen IC, Lemming L, Gerdes U, Gregersen N, Faergeman O. Characteristics of 46 heterozygous carriers and 57 unaffected relatives in five Danish families with familial defective apolipoprotein B-100. *Arterioscler Thromb*. 1994 Feb;14(2):207-13.
79. **Hansen PS**, Klausen IC, Lemming L, Gerdes LU, Gregersen N, Faergeman O. Apolipoprotein B gene polymorphisms in ischemic heart disease and hypercholesterolemia: effects of age and sex. *Clin Genet*. 1994 Feb;45(2):78-83.
80. **Hansen PS**, Gerdes LU, Klausen IC, Gregersen N, Faergeman O. Genotyping compared with protein phenotyping of the common apolipoprotein E polymorphism. *Clin Chim Acta*. 1994 Jan 31;224(2):131-7.
81. Jensen HK, Jensen TG, Jensen LG, **Hansen PS**, Kjeldsen M, Andresen BS, Nielsen V, Meinertz H, Hansen AB, Bolund L, et al. Characterization of a disease-causing Glu119-Lys mutation in the low-density lipoprotein receptor gene in two Danish families with heterozygous familial hypercholesterolemia. *Hum Mutat* 1994;4(2):102-13.
82. Klausen IC, **Hansen PS**, Gerdes LU, Rüdiger N, Gregersen N, Faergeman O. A Pvull polymorphism of the low density lipoprotein receptor gene is not associated with plasma concentrations of low density lipoproteins including LP(a). *Hum Genet*. 1993 Mar;91(2):193-5.
83. **Hansen PS**, Gerdes LU, Klausen IC, Gregersen N, Faergeman O. Polymorphisms in the apolipoprotein B-100 gene contributes to normal variation in plasma lipids in 464 Danish men born in 1948. *Hum Genet*. 1993 Mar;91(1):45-50.
84. **Hansen PS**, Sølling J, Knudsen TE, Faergeman O. [Non-dietary, non-pharmacological treatment of severe hypercholesterolemia]. *Ugeskr Laeger*. 1991 Jul 15;153(29):2046-51. Review. Danish.
85. **Hansen PS**, Rüdiger N, Tybjaerg-Hansen A, Faergeman O, Gregersen N. Detection of the apoB-3500 mutation (glutamine for arginine) by gene amplification and cleavage with MspI. *J Lipid Res*. 1991 Jul;32(7):1229-33.
86. Ravkilde JL, **Hansen PS**. Late results following closed mitral valvotomy in isolated mitral valve stenosis: analysis of thirty-five years of follow-up in 240 patients using Cox regression. *Thorac Cardiovasc Surg*. 1991 Jun;39(3):133-9.
87. Rüdiger NS, **Hansen PS**, Jørgensen M, Faergeman O, Bolund L, Gregersen N. Repetitive sequences involved in the recombination leading to deletion of exon 5 of the low-density-lipoprotein receptor gene in a patient with familial hypercholesterolemia. *Eur J Biochem*. 1991 May 23;198(1):107-11.